Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TRML
TRML logo

TRML Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
996.54M
EV/OCF(TTM)
--
P/S(TTM)
--
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company. The Company is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Company’s initial product candidate is pacibekitug (TOUR006), a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. It is focused on two strategic paths for TOUR006, the first of which is cardiovascular inflammation. Its second strategic path is thyroid eye disease (TED). TED is an autoimmune disease characterized by autoantibody-mediated activation of the tissues surrounding the eye, causing inflammation and disfigurement which can be sight-threatening in severe cases.
Show More

Events Timeline

(ET)
2025-10-28
10:06:20
Novartis Finalizes Acquisition of Tourmaline Bio
select
2025-10-28
06:15:36
Novartis Declares End of Tourmaline Bio Tender Offer
select
2025-10-22 (ET)
2025-10-22
07:00:16
Novartis Declares End of HSR Act Waiting Period for Tourmaline Bio Acquisition
select
2025-09-09 (ET)
2025-09-09
16:09:45
Chardan Lowers Tourmaline Bio Rating from Buy to Neutral
select

News

Benzinga
4.0
2025-10-29Benzinga
Cantor Fitzgerald Halts Overweight Rating for Tourmaline Bio
  • Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.

  • Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.

  • Market Intelligence: Benzinga Pro is positioned as a source for the fastest and most accurate stock market intelligence available.

WSJ
8.5
2025-10-26WSJ
Novartis to Purchase Avidity Biosciences for $12 Billion
  • Acquisition Announcement: Novartis is acquiring Avidity Biosciences for $12 billion to enhance its focus on neuromuscular disorder treatments.

  • Company Background: Avidity Biosciences is a biotech firm based in San Diego.

  • Exclusion of Subsidiary: The acquisition does not include Avidity's subsidiary that is working on early-stage heart disease treatments.

  • Strategic Focus: This deal aligns with Novartis's long-term strategy to strengthen its portfolio in the neuromuscular disorder space.

PRnewswire
7.0
2025-10-17PRnewswire
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HSII, VECO, CMA, TRML on Behalf of Shareholders
  • Investigation of Companies: Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sales of Heidrick & Struggles, Veeco Instruments, Comerica, and Tourmaline Bio.

  • Shareholder Rights and Legal Options: Shareholders of the mentioned companies are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options, with the firm offering services on a contingent fee basis.

Globenewswire
8.5
2025-10-17Globenewswire
BRODSKY & SMITH INVESTOR ALERT: Announcing Investigations into Heidrick & Struggles International, Inc. (Nasdaq - HSII), Comerica Incorporated (NYSE - CMA), Veeco Instruments Inc. (Nasdaq - VECO), and Tourmaline Bio, Inc. (Nasdaq - TRML)
  • Investigations Announced: Brodsky & Smith is reminding investors of ongoing investigations into several companies regarding potential breaches of fiduciary duties by their boards during merger agreements.

  • Heidrick & Struggles Acquisition: Heidrick & Struggles is set to be acquired for $59.00 per share by a consortium led by Advent International and Corvex Private Equity, with concerns about the fairness of the deal for shareholders.

  • Comerica and Fifth Third Merger: Comerica will be acquired by Fifth Third Bancorp, with shareholders receiving shares equivalent to $82.88 per share, raising questions about the fairness of the transaction process.

  • Veeco and Tourmaline Mergers: Veeco will merge with Axcelis Technologies, and Tourmaline will be acquired by Novartis for $48.00 per share, both facing investigations regarding the fairness of the deal terms for shareholders.

Globenewswire
7.0
2025-10-08Globenewswire
SHAREHOLDER RIGHTS NOTICE: Halper Sadeh LLC Probes TRML, CCRD, PBBK for Shareholder Advocacy
  • Investigation of Companies: Halper Sadeh LLC is investigating Tourmaline Bio, CoreCard Corporation, and PB Bankshares for potential violations of federal securities laws and breaches of fiduciary duties related to their recent sales.

  • Shareholder Rights: Shareholders of the mentioned companies are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options regarding the proposed transactions, with the firm offering services on a contingent fee basis.

Globenewswire
8.5
2025-10-08Globenewswire
Shareholder Update: Ongoing Class Action Investigation into Merger Involving TRML, PNFP, MRCC, and UNP
  • Class Action Firm Recognition: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders.

  • Ongoing Investigations: The firm is currently investigating several companies, including Tourmaline Bio, Pinnacle Financial Partners, Monroe Capital Corporation, and Union Pacific Corporation, regarding their proposed mergers and acquisitions, with specific shareholder actions and deadlines highlighted.

Wall Street analysts forecast TRML stock price to rise
9 Analyst Rating
Wall Street analysts forecast TRML stock price to rise
1 Buy
8 Hold
0 Sell
Hold
Current: 0.000
sliders
Low
47.50
Averages
47.93
High
48.00
Current: 0.000
sliders
Low
47.50
Averages
47.93
High
48.00
BMO Capital
Kostas Biliouris
Outperform
to
Market Perform
downgrade
$35 -> $48
AI Analysis
2025-09-14
Reason
BMO Capital
Kostas Biliouris
Price Target
$35 -> $48
AI Analysis
2025-09-14
downgrade
Outperform
to
Market Perform
Reason
BMO Capital analyst Kostas Biliouris downgraded Tourmaline Bio (TRML) to Market Perform from Outperform with a price target of $48, up from $35, after the company agreed to be acquired by Novartis (NVS) for $48 per share or $1.4B. BMO expects a \"smooth\" deal closure by Q4 without material antitrust concerns.
Piper Sandler
Overweight
to
Neutral
downgrade
$65 -> $48
2025-09-11
Reason
Piper Sandler
Price Target
$65 -> $48
2025-09-11
downgrade
Overweight
to
Neutral
Reason
Piper Sandler downgraded Tourmaline Bio (TRML) to Neutral from Overweight with a price target of $48, down from $65, after the company agreed to be acquired by Novartis (NVS) for $1.4B in cash, or $48 per share.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for TRML
Unlock Now

Valuation Metrics

The current forward P/E ratio for Tourmaline Bio Inc (TRML.O) is -4.85, compared to its 5-year average forward P/E of -6.44. For a more detailed relative valuation and DCF analysis to assess Tourmaline Bio Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.44
Current PE
-4.85
Overvalued PE
-3.72
Undervalued PE
-9.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
24.46
Current PS
55.63
Overvalued PS
66.60
Undervalued PS
-17.67

Financials

AI Analysis
Annual
Quarterly

Whales Holding TRML

V
Vivo Capital, LLC
Holding
TRML
+7.04%
3M Return
T
TCG Crossover Management, LLC
Holding
TRML
-2.27%
3M Return
A
Avoro Capital Advisors LLC
Holding
TRML
-4.17%
3M Return
R
RA Capital Management, L.P.
Holding
TRML
-6.55%
3M Return
N
Nantahala Capital Management, LLC
Holding
TRML
-15.93%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Tourmaline Bio Inc (TRML) stock price today?

The current price of TRML is 0 USD — it has increased 0

What is Tourmaline Bio Inc (TRML)'s business?

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company. The Company is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Company’s initial product candidate is pacibekitug (TOUR006), a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. It is focused on two strategic paths for TOUR006, the first of which is cardiovascular inflammation. Its second strategic path is thyroid eye disease (TED). TED is an autoimmune disease characterized by autoantibody-mediated activation of the tissues surrounding the eye, causing inflammation and disfigurement which can be sight-threatening in severe cases.

What is the price predicton of TRML Stock?

Wall Street analysts forecast TRML stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRML is47.93 USD with a low forecast of 47.50 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Tourmaline Bio Inc (TRML)'s revenue for the last quarter?

Tourmaline Bio Inc revenue for the last quarter amounts to -25.97M USD, increased 18.22

What is Tourmaline Bio Inc (TRML)'s earnings per share (EPS) for the last quarter?

Tourmaline Bio Inc. EPS for the last quarter amounts to -20271000.00 USD, increased 12.57

How many employees does Tourmaline Bio Inc (TRML). have?

Tourmaline Bio Inc (TRML) has 74 emplpoyees as of March 31 2026.

What is Tourmaline Bio Inc (TRML) market cap?

Today TRML has the market capitalization of 0.00 USD.